

# Association of Polybrominated Diphenyl Ether (PBDE) Levels with Biomarkers of Placental Development and Disease during Mid-gestation

**Julia Varshavsky** (✉ [julia.varshavsky@ucsf.edu](mailto:julia.varshavsky@ucsf.edu))

University of California San Francisco <https://orcid.org/0000-0001-6891-7083>

**Joshua F. Robinson**

University of California San Francisco

**Yan Zhou**

University of California San Francisco

**Kenisha A. Puckett**

University of California San Francisco

**Elaine Kwan**

University of California San Francisco

**Sirirak Buarpong**

University of California San Francisco

**Rayyan Aburajab**

University of California San Francisco

**Stephanie L. Gaw**

University of California San Francisco

**Saunak Sen**

University of Tennessee Health Science Center

**Sabrina Crispo Smith**

California Department of Toxic Substances Control

**Julie Frankenfield**

California Department of Toxic Substances Control

**June-Soo Park**

California Department of Toxic Substances Control

**Susan J. Fisher**

University of California San Francisco

**Tracey J. Woodruff**

University of California San Francisco

**Keywords:** Flame retardants, biomonitoring, developmental/reproductive health effects, endocrine disruption, preeclampsia, pregnancy complications, maternal health, birth outcomes, cytotrophoblast differentiation

**Posted Date:** December 19th, 2019

**DOI:** <https://doi.org/10.21203/rs.2.19137/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published at Environmental Health on June 3rd, 2020. See the published version at <https://doi.org/10.1186/s12940-020-00617-7>.

# Abstract

## Background

Polybrominated diphenyl ether (PBDE) exposures have been associated with adverse pregnancy outcomes. A hypothesized mechanism is via alterations in placental development and function. However, we lack biomarkers that can be used as early indicators of maternal/fetal response to PBDE exposures and/or perturbations in placental development or function.

## Methods

To evaluate the relationship between PBDE levels and placental biomarkers during mid-gestation of human pregnancy ( $n = 62$ ), we immunolocalized three molecules that play key roles in cytotrophoblast (CTB) differentiation and interstitial/endovascular uterine invasion—integrin alpha-1 (*ITGA1*), vascular endothelial-cadherin (*CDH5*), and metalloproteinase-1 (*MMP1*)—and assessed three morphological parameters as potential indicators of pathological alterations using H&E-stained tissues—leukocyte infiltration, fibrinoid deposition, and CTB endovascular invasion. We evaluated associations between placental PBDE levels and of biomarkers of placental development and disease using censored Kendall's tau correlation and linear regression methods.

## Results

PBDEs were detected in all placental samples. We observed substantial variation in antigen expression and morphological endpoints across placental regions. We observed an association between PBDE levels and immunoreactivity of endovascular CTB staining with anti-ITGA1 (inverse) or interstitial CTBs staining with anti-CDH5 (positive).

## Conclusions

We found several molecular markers that may be sensitive placental indicators of PBDE exposure. Further, this indicates that placental biomarkers of development and disease could be useful barometers of exposure to PBDEs, a paradigm that could be extended to other environmental chemicals and placental stage-specific antigens.

## 1. Background

Pregnancy complications, such as preterm birth, gestational diabetes, fetal growth restriction, hypertension, and preeclampsia, are significantly linked with adverse maternal and fetal health outcomes [1], and environmental exposures are important risk factors [2–4]. Environmental chemicals can exert their influence on pregnancy through multiple mechanisms, including alterations in placental development and function.

The placenta plays an essential role in development, supporting embryonic/fetal growth and maternal adaptations to the changing physiology of pregnancy [5,6]. The human placenta consists of tree-like chorionic villi that float in maternal blood (floating villi, FV; **Figure 1**). Mononuclear cytotrophoblast (CTB) progenitors fuse to form multinucleated syncytiotrophoblasts (STBs) that cover the villus surface where they regulate the exchange of nutrients, waste, and gases. A subset of chorionic villi called anchoring villi (AV) attach the placenta to the uterus. CTBs migrate through the AV and form cell columns that are the source of the extravillous subpopulation which invades the uterus and maternal vasculature. Vascular CTB remodeling of uterine arteries redirects blood flow to the placenta, maximizing nutrient uptake for embryonic/fetal growth and development over the course of gestation [7]. During normal pregnancy, modulation of numerous molecules characterized by migratory and invasive properties facilitate CTB differentiation along this pathway: extracellular matrix (ECM)-degrading metalloproteinases (*e.g.*, MMPs), cell-ECM (*e.g.*, ITGAs), and cell-cell adhesion molecules (*e.g.*, CDHs). The net effect is a unique epithelial to vascular transformation [8] critical for placental development and function. For example, CTBs upregulate the expression of ITGA5/B1, A1/B1 while down regulating ITGA6/B4 [9]. Furthermore, as CTBs become invasive and enter cell columns, they down regulate CDH1 and up regulate CDH5 [7,9–11]. Placental development (placentation) is especially critical during mid-gestation, an important time of fetal organogenesis and extreme changes to maternal physiology [4].

Disruption of the balance of adhesion receptor molecules and/or matrix-degrading proteins is associated with pregnancy complications (*e.g.*, preeclampsia) that can be due to alterations in CTB differentiation which lead to incomplete vascularization. For example, in severe preeclampsia, CTB remodeling of maternal vasculature is incomplete, which is thought to contribute to shallow placentation and reduced arterial invasion that are the hallmarks of this syndrome (Fisher, 2017). While specialized subpopulations of immune cells co-occupy the pregnant uterus with placental CTBs, aiding in vascular remodeling [12], excessive leukocyte infiltration can indicate infection, a major risk factor for preterm birth (Romero et al., 2015). Excessive perivillous fibrinoid deposition is also associated with pregnancy complications that either directly or indirectly involve abnormal placentation [13].

Diverse environmental exposures—including heavy metals (*i.e.*, lead and cadmium [14,15]) and common classes of endocrine disrupting chemicals (EDCs), such as polybrominated diphenyl ethers (PBDEs), per- and polyfluorinated alkyl substances (PFAS), and phthalates—are suspected to contribute to maternal health and pregnancy complications by interfering with placental development and function [16]. However, we know very little about the precise mechanisms by which EDCs exert their toxic effects. Despite ongoing efforts to restrict their use as flame retardants, PBDEs remain a global public health concern due to their environmental and biological persistence [17]. Human pregnancy is a period of high sensitivity and susceptibility; meanwhile, PBDEs are commonly identified in placental/fetal tissues [18,19], and exposures have been associated with maternal health complications [4], adverse birth outcomes [20], and postnatal neurodevelopmental deficits (*i.e.*, lowered IQ; [21]). North Americans typically have higher body burden levels due to historically strict flammability standards in the United States (implemented in the 1970s), with some of the highest levels ever reported among pregnant women in the State of California [22].

In humans, the relationship between PBDE exposures and pregnancy complications (e.g., preeclampsia) remains undefined. However, in mice and/or human cell lines, PBDEs alter hormone production [23], elicit inflammation [24–26], and promote oxidative stress [24,27–31]. Previously, we studied the effects of PBDEs in an *in vitro* model of CTB differentiation along the invasive pathway. The results showed that PBDEs impaired the cells' ability to migrate and invade due to altered gene expression in CTB differentiation and environmental stress response pathways (Robinson et al., 2019). Together, these studies indicate a potential role for PBDEs in the pathophysiology of adverse pregnancy outcomes via effects on the placenta, and highlight functional and molecular perturbations to human placental development that can be evaluated in relation to PBDE exposures.

Accordingly, we examined the relationship between mid-gestational PBDE levels and biomarkers of placental development and disease, focusing on molecular and morphological features that: 1) correlate with normal placentation and pregnancy outcomes; 2) are adversely affected in pregnancy complications; and/or 3) are differentially expressed following exposure of primary human CTBs to PBDEs *in vitro* (Robinson et al., 2019). The molecules were stage-specific CTB antigens that correlate with differentiation and invasion: ITGA1, CDH5, and MMP1. The morphological features evaluated were leukocyte infiltration, fibrinoid deposition, and CTB arterial vascular remodeling. Additionally, this study will advance new methods and findings that will contribute to better understanding the relationship between biomarkers of chemical exposure and potential biomarkers of placental development and disease (**Figure S1**).

## 2. Methods

### 2.1 Study Recruitment and Sample Collection

Non-smoking pregnant women ( $n = 138$ ) with uncomplicated pregnancies undergoing elective terminations during mid-gestation of pregnancy (gestational week [GW] 15-24) were recruited at the Women's Options Center (WOC) in the San Francisco Bay Area from 2014–16. The WOC serves a racially/ethnically diverse low-income population of pregnant women in Northern and Central California who tend to rely on public health insurance coverage for prenatal care. Written and verbal consents were obtained during the clinical visit, followed by administration of a survey questionnaire to each study participant. All study protocols were approved by the UCSF Institutional Review Board prior to the clinical visit.

We collected the following biological samples—maternal serum, placenta, and fetal liver ( $n = 141$ , due to three sets of twins)—from study participants during or immediately following the clinical procedure. Chemical PBDE analyses were performed on  $n = 135$  placental samples, with  $n = 130$  matched samples (excluding twins) of all three biomatrices (**Figure 2**). For the chemical analyses, maternal serum samples were centrifuged at 3000 RPM for 10 min at 4°C prior to aliquoting and transfer of the serum with glass pipettes into pre-screened (to confirm absence of PBDE) sterilized amber vials (storage at -80°C). A subset of placental samples ( $n = 62$ ) was further processed and evaluated for three molecular and

morphological features (see below). Placental tissues were submerged in medium (DME/H-21 [Gibco], 12.5% fetal bovine serum [Hyclone], 1% glutamine plus [Atlanta Biologicals], 1% penicillin/streptomycin [Invitrogen], and 0.1% gentamicin [Gibco]); dissected into 1 x cm<sup>3</sup> pieces; fixed with 3% paraformaldehyde (PFA); and frozen in Optimal Cutting Temperature (OCT) medium (Sakura Finetek, SA62550-01) in a cryomold at -80°C [32]. Placental biopsies were later sectioned (5µM thickness) using a cryostat (Leica) and placed on glass slides for molecular and morphological assessments.

## 2.2 Chemical Exposure Assessment

Nineteen PBDE congeners (including BDE-17, -28, -47, -66, -85, -99, -100, -153, -154, -183, -196, -197, -201, -202, -203, -206, -207, -208, and -209) were analyzed in maternal serum, placenta, and fetal liver by the Environmental Chemistry Laboratory at California's Department of Toxic Substances Control in Berkeley, CA, using gas chromatography–high-resolution mass spectrometry (GC–HRMS, DFS, ThermoFisher, Bremen, Germany). Isotopically-labeled internal surrogate mix standards (IS) were used for quantitation (Wellington Laboratories, Inc., Guelph, Ontario, Canada).

Thawed serum samples (1 mL) were spiked with carbon-labeled internal standards (<sup>13</sup>C<sub>12</sub>-BDE-28, 47, 99, 153, 154, 183, 197, 207, and 209), with 4 mL each of formic acid and water added. Serum samples were vortexed and loaded into an automated sample extraction system (RapidTrace, Biotage; Uppsala Sweden). Oasis HLB cartridges (3 cc, 500 mg, Waters Corp.; Milford, MA) were used for sample extraction and acidified silica (500 °C prebaked, manually packed, 3 cc) for sample extraction cleanup. Final eluates were concentrated 10-fold using an automated nitrogen evaporation system (TurboVap LV, Biotage; Uppsala, Sweden) and spiked with a <sup>13</sup>C<sub>12</sub>-PCB-209 recovery standard [33,34]. Total cholesterol and triglycerides were measured enzymatically by Boston Children's Hospital (Boston, MA) and subsequently used to calculate the total serum lipid level for each study participant using the Phillips formula [35]. Fetal liver and placental samples were analyzed using our liver analytical method with slight modification [19]. Before sample extraction, only placenta samples were lyophilized. Briefly, samples were homogenized and spiked with the same internal standards (listed above). Samples were then denatured with hydrochloric acid and extracted with 1:1 hexane:methyl tert-butyl ether (MTBE). Aqueous potassium chloride solution was added to each sample extract to remove potentially co-extracted aqueous compounds and the organic layer was re-extracted and dried in a pre-weighed, pre-baked aluminum weighing dish for lipid content determination via gravimetric analysis. Samples were then reconstituted in hexane and lipids were removed using concentrated sulfuric acid, followed by cleanup with acidified silica (500 °C prebaked, manually packed, 3 cc) on automated SPE system (RapidTrace, Biotage; Uppsala Sweden).

## 2.3 Assessment of Stage-Specific Antigens and Morphological Endpoints

Molecular and morphological placental features were evaluated independently by two investigators who were blinded to PBDE exposure levels. We assessed molecular immunoreactivity of CTBs at the maternal-fetal interface with antibodies specific for ITGA1, CDH5 or MMP1 in five stages of trophoblast

differentiation: Zone I) CTBs resident in FV; Zone II) CTBs in the proximal (p) regions of AV cell columns; Zone III) CTBs within the distal (d) regions of AV cell columns; Zone IV) interstitial invasive/extravillous CTBs (iCTB); and Zone V) endovascular CTBs (eCTB) (**Figure 1**). We selected ITGA1 and CDH5 based on previous *in vitro* and *in vivo* literature demonstrating the importance of these adhesion receptor molecules in placental development and function (specifically regarding invasive and endovascular CTB differentiation pathways that are critical for vascular remodeling) as well as their potential disease associations. MMP1 is a metalloproteinase matrix-degrading enzyme that facilitates CTB migration/invasion during placentation [7,9,36] (**Table S1 and Figures S3–S5**). We immunolocalized ITGA1, CDH5, and MMP1 in each placental zone using published methods (Zhou et al., 2003). The antibodies and dilutions that were used for this purpose are described in (**Table S2**). CTBs were identified by reactivity with CK7. Batch effects which influence immunofluorescence (IF) intensity were continuously monitored by including serial sections from the same two placental samples in each assessment. Slides were imaged using an upright Leica DFC450 microscope equipped with a camera and Leica Advanced Fluorescence Application Suite Ver. 3.2 (Leica Microsystems). Immunoreactivity was scored into three groups based on the percentage of CTBs that reacted with each antibody: 1) < 25% (-); 2) 25–75% (-/+); and 3) > 75% (+).

Placental biopsies were also stained with Hematoxylin and Eosin (H&E) to evaluate morphological features: (1) average total number of white blood cells (WBC) present in basal plate (BP) per 10X field; (2) percent of FV with perivillous fibrinoid deposits (~ 60 villi evaluated per field); 3) fibrinoid deposition at the utero-placental junction; and (4) total number of modulated uterine spiral arteries which contained CTBs (defined as presence of > 50% endovascular CTBs in the lining of uterine spiral arteries) (**Table S1 and Figure S5**). All values were based on examination of the entire placental section at 10X resolution (~6-10 independent fields). In total, we evaluated 62 placentas; however, the sample size for each molecular and morphological endpoint varied depending on whether tissue sections captured the key structures of interest, most notably uterine arteries. For example, eCTB were confined to placental tissue sections that contained uterine arteries (n = 29–42); pAV and dAV CTBs were observed in 51–53 samples, and iCTB were found in 60 samples (**Table S3**). For morphological assessments, one sample was lost while processing (n = 61 placentas evaluated). Images were acquired using a bright field Leica DFC450 microscope equipped with a camera (**Figure S5**).

## 2.4 Statistical Analysis

We calculated detection frequencies for all 19 PBDE congeners in matched samples of maternal serum, fetal liver, and placental tissues obtained in this study (2014–16; n = 130) (**Table S4**). We normalized wet-weight PBDE concentrations to total lipid levels in order to account for possible measurement error related to estimating PBDE exposure from biomonitoring data, since biological proxies of exposure to PBDEs and other lipophilic compounds can vary systematically with population characteristics (*e.g.*, lipid content, BMI) rather than the PBDE exposures they represent [37,38]. For five PBDE congeners (BDE-28, -47, -99, -100, and -153) detected in > 50% of placental samples (n = 135), we further calculated wet-weight and lipid-adjusted descriptive statistics, including geometric mean, interquartile range (25<sup>th</sup>–75<sup>th</sup>

percentile), and range (min–max). We also computed a summary PBDE metric by adding four of congeners ( $\Sigma$ PBDE4 = BDE-47, -99, -100, and -153) with detection frequencies > 50% in all maternal-fetal tissues, in order to facilitate results comparison with maternal serum and fetal liver in secondary analyses. We used maximum likelihood estimation (MLE) assuming a log-normal distribution to account for PBDE levels below the laboratory method detection limit (MDL) [39]. Statistical analyses were performed using R (Version 3.5.1) [40], with significance defined as  $p < 0.05$  and marginal significance as  $p < 0.10$  (two-sided tests).

In addition, we computed descriptive statistics for molecular and morphological placental biomarker data. We natural log-transformed average WBC counts prior to statistical analysis based on visual inspection of right-skewed distribution as well as results from the Shapiro-Wilk statistical test. One observation had a WBC count of zero which we set to 0.01 prior to log transformation. We calculated the percent of modulated uterine spiral arteries by dividing the number of uterine spiral arteries with > 50% endovascular CTB modulation by the total number of uterine spiral arteries observed. If the total number of uterine spiral arteries (*i.e.*, the denominator) was zero or less than two, the denominator and percent modulation were re-coded as missing. Then we divided % CTB-modulated uterine blood vessels (mBV) at the median and categorized the variable into two groups (low and high).

Kendall's Tau Correlation Coefficient [41], a non-parametric measure of correlation that compares concordant and discordant pairs of ordered data to determine the extent of increasing or decreasing covariation between two variables, was used to evaluate monotonic relationships: 1) among molecular and morphological placental biomarkers; and 2) between placental biomarkers (molecular and morphological) and placental PBDE levels (wet-weight and lipid-normalized). We calculated the correlation between placental biomarkers and PBDE levels using the censored version of Kendall's tau [42]. We adjusted for multiple comparisons by estimating the false discovery rate (FDR) using the Benjamini and Hochberg method [43].

To compare PBDE levels across immunoreactivity groups, we tested group mean differences (assuming a log-normal PBDE distribution) using MLE to account for left-censored PBDE data [39]. From these bivariate censored regression/ANOVA models, we calculated pairwise percent (%) differences in PBDE levels as  $(e^{\beta} - 1) * 100$  and the 95% confidence interval (95% CI) as  $(e^{\beta \pm 1.96 * SE} - 1) * 100$ , where the referent group comprised placental samples in the < 25% (-) immunoreactivity group. We also used the Fisher's exact test to examine whether molecular immunoreactivity varied by high/low PBDE exposure (where PBDE levels were divided at the median and categorized into high vs. low exposure groups).

### 2.4.1 Secondary Analysis

In a secondary analysis, we re-examined placental biomarker associations with fetal liver and maternal serum PBDE levels, since we previously found moderate correlation between congeners across maternal-fetal tissues during mid-gestation (Varshavsky et al., *Submitted*), with cross-tissue correlations ranging from 0.18 (BDE-99) to  $\geq 0.50$  (BDE-47, -100, and -153) ( $p < 0.0001$ ).

### 3. Results

The majority of women in our study population ( $n = 135$ ) were  $< 30$  yrs old (79%); participants 20–24 yrs old were the largest age subgroup (43%; **Table 1**). Gestational age ranged from  $\sim 15$ –24 wks (median = 20 wks). Most women were classified as overweight (28%; BMI = 25-30 kg/m<sup>2</sup>) or obese (29%; BMI  $\geq 30$  kg/m<sup>2</sup>). Approximately 60% of participants had at least one prior live birth and 54% of the pregnancies were with a male fetus. Education level was evenly divided between high school attendance or graduation and some post-secondary schooling. Most women used public rather than private health insurance. The study population was racially/ethnically diverse ( $> 50\%$  Latina/Hispanic and non-Hispanic Black) (**Table 1**).

PBDEs were detected in all placental samples, with the range of wet-weight PBDE levels spanning more than one order of magnitude, and lipid-adjusted PBDE levels greater than wet-weight levels by almost two orders of magnitude (**Table 1**). Placental PBDE levels did not vary by maternal age, gestational age, BMI, parity, fetal sex, education, or insurance type ( $p > 0.05$ ). In contrast, we observed placental PBDE exposure differences based on race/ethnicity, birth country, and sample collection year. More specifically, placental PBDE levels were highest among US-born participants, Non-Hispanic Black women, and in earlier collection years (2016  $>$  2014  $>$  2015) (**Table 1**), which is consistent with our previous findings (Varshavsky et al., *Submitted*).

ITGA1, CDH5, and MMP1 immunoreactivity was in accord with previously published results [7,9,36]. These stage-specific antigens were upregulated as CK-positive CTBs exited the placenta and invaded the uterine wall ( $p < 0.001$ ) (**Figure 3 and Table S3**). Staining patterns varied by region and antibody target. For example, ITGA1 immunoreactivity was minimally detected in FV CK+ CTBs and upregulated as the cells differentiated and invaded, increasingly detected in association with pAV, dAV, iCTB, and eCTB CTBs. CDH5 immunoreactivity had a similar pattern except that FV CK+ CTBs in a few samples expressed this cell-cell adhesion molecule. With the exception of eCTB, MMP1 was more widely expressed by the CTB subpopulations on which we focused.

On average, WBC infiltration was  $212 \text{ cells} \pm 174$  (**Table 2**). The percentage of FV with associated fibrin deposits was  $13.4 \pm 10.4$ , while fibrinoid deposition in the BP delimited  $22.6 \pm 19.6\%$  of the CTB-decidual boundary. In a subset of placental biopsies ( $n = 38$ ) with at least three uterine spiral arteries,  $71.7 \pm 30.4\%$  of blood vessels were modulated, defined as having  $>50\%$  CK-positive CTBs within the walls or lumens. As expected given the narrow range in gestational age, correlations between morphological features and weeks of pregnancy were not significant. The exception was possible evidence of an inverse relationship between perivillous fibrinoid deposition and gestational age ( $\tau = -0.28$ ;  $p = 0.001$ ) (**Table 2**).

The rank order correlation of ITGA1, CDH5, and MMP1 immunoreactivity varied among molecules and placental region/cell type (**Tables S5 and S6**). Molecular markers were more highly correlated between CTB subtypes that were closely related on a developmental continuum and located in proximity to one another (iCTB and eCTB; pAV and dAV). For example, previous studies showed that the stage-specific

antigens of interest are upregulated as the cells leave the placenta and invade the uterine wall [7,9,36]. Accordingly, MMP1 immunoreactivity in CK+ cells was positively correlated between CTBs in pAV and dAV ( $\tau = 0.42$ ;  $p < 0.001$ ), dAV CTBs and iCTB ( $0.46$ ;  $p < 0.001$ ), and iCTB and eCTB ( $\tau = 0.32$ ,  $p = 0.05$ ); there was no correlation between CTBs in FV and pAV ( $0.07$ ;  $p = 0.63$ ). As expected, we found ITGA1 and CDH5 were similarly regulated. Interestingly, while we found no-to-low correlation between ITGA1 and CDH5 immunoreactivity, regardless of placental region/cell type, MMP1 immunoreactivity was modestly correlated with the other two molecular markers. We found little association among the morphological endpoints except for a positive correlation between fibrinoid deposition in the FV and basal plate ( $\tau = 0.24$ ,  $p = 0.01$ ). The correlation between molecular and morphological biomarkers was also largely null. However, several trends were notable, including a consistent inverse correlation between immunoreactivity for MMP1 ( $\tau = -0.27$ ;  $p = 0.02$ ), ITGA1 ( $\tau = -0.21$ ;  $p = 0.07$ ), and CDH5 ( $\tau = -0.26$ ;  $p = 0.02$ ) in dAV and WBC count. There was also an inverse association between expression of these stage specific antigens and fibrinoid deposition in some regions. For example, reduced MMP1 immunoreactivity ( $\tau = -0.29$ ;  $p = 0.01$ ) in CTBs of the dAV and the percent of floating villi with fibrinoid deposits and vice versa. Adjusting for multiple comparisons did not substantially change overall correlation patterns between molecular and morphological biomarkers (**Tables S5 and S6**).

In general, we did not observe significant correlations between PBDE levels (BDE-47 or  $\Sigma$ PBDEs) and most molecular or morphological biomarkers (**Table S7**). The exception was an inverse relationship between ITGA1 immunoreactivity in eCTB with levels of most PBDE congeners, individually and as a group. For example, BDE-47 was inversely correlated with eCTB ITGA1 ( $\tau = -0.25$ ,  $p < 0.05$ ). Similar inverse relationships were observed for congeners -99, -100, and  $\Sigma$ PBDE4 but were attenuated for BDE-28 and BDE-153. We also found a positive correlation between BDE-28 and MMP1 immunoreactivity in iCTB ( $\tau = 0.18$ ,  $p = 0.01$ ). Correlations with lipid-adjusted PBDE levels were similar and thus not reported. Adjusting for multiple comparisons revealed the potential for false positive findings (**Table S7**), suggesting these observations could be strengthened by analyzing more samples.

The analysis revealed a similar inverse trend in the magnitude of ITGA1 immunoreactivity and placental levels of PBDE congeners. For example, placentas with the highest levels of ITGA expression in eCTB had 42% (95% CI: -69–7.2%,  $p = 0.08$ ) lower levels of  $\Sigma$ PBDE4 compared to the referent group (**Table 3 and Figure 4**). The magnitude and direction of association with CTBe ITGA-1 immunoreactivity was consistent for all congeners, despite ANOVA tests which did not reveal an overall difference between groups ( $p > 0.05$ ). We also found a positive association between wet-weight and lipid-adjusted placental BDE-47 or  $\Sigma$ PBDE4 levels and CDH5 immunoreactivity in iCTB ( $p < 0.05$ ). The same relationship held for eCTB, although at a lower level of statistical significance (**Table 3 and Figure 4**).

We observed a similar pattern of results for PBDEs in maternal serum and the fetal liver, with ITGA1 (eCTB) and CDH5 (iCTB) associations and correlations that persisted with lipid-adjustment and were strongest in the fetal liver (**Supplemental Spreadsheet**).

## 4. Discussion

We profiled placental molecular and morphological biomarkers in relationship to PBDE levels in maternal and fetal tissues at mid-gestation of human pregnancy. The results suggested possible associations—an inverse correlation between PBDE exposures and ITGA1 immunoreactivity (endovascular CTBs) and a positive correlation between PBDE exposures and CDH5 immunoreactivity (interstitial and endovascular CTBs). This is one of the first studies to characterize placental biomarkers and PBDE exposures during mid-gestation among a diverse population of women with uncomplicated pregnancies.

First, we immunolocalized three molecules (ITGA1, CDH5, MMP1) in biopsies of the basal plate (**Figures 1 and 3**). ITGA1 and CDH5 play key roles in CTB differentiation and have potential disease associations (*e.g.*, preeclampsia) [7,9,11]. MMP1 was upregulated by exposing differentiating/invading CTBs to BDE-47 (Robinson et al., 2019). In agreement with previously published data [32], ITGA1 was upregulated in cell columns and primarily expressed in extravillous CTBs (iCTB and eCTB). Corresponding with previous observations [7], CDH5 had a similar expression pattern. MMP1 is thought to be involved in extracellular matrix (ECM) breakdown during CTB invasion [44]. We confirmed upregulated anti-MMP1 reactivity associated with CTBs of the cell column, iCTB, and eCTB. Thus, the stage-specific antigens we profiled are upregulated as part of the molecular program that enables placental attachment to the uterus and arterial remodeling.

The interpretation of these immunostaining patterns in relation to placental PBDE levels was more complicated. Motivated by our *in vitro* exposure data showing that BDE-47 inhibits CTB migration and invasion, we investigated whether PBDE exposures *in vivo* were associated with reduced immunoreactivity of molecules that are upregulated during these processes. The association between decreased ITGA1 expression in endovascular CTBs and high levels of PBDE exposures was consistent with this hypothesis. However, we also observed a positive association between these exposures and enhanced immunoreactivity for CDH5 in iCTB and eCTB.

There are many potential explanations for these seemingly discordant results. Perhaps upregulated CDH5 compensates for downregulated ITGA1. Also placental development is complex, involving a large constellation of molecules, including numerous families of adhesion molecules and proteinases as well as their inhibitors. Moreover, we were not able to account for other exposures. For example, Bisphenol-A (BPA), an endocrine disrupting compound can promote trophoblast migration and disrupt placentation in mice by increasing the expression of invasion-promoting integrins (*i.e.*, ITGB2 and ITGA5) and metalloproteinases (*i.e.*, MMP-2 and MMP-9) [45]. Thus, the complexity of CTB invasion in the context of the exposome make it difficult to predict the outcome of experiments such as those described here. As to the MMP1 analyses, the effects of *in vitro* PBDE exposures were analyzed at the RNA level [46] as compared to the antibody-based protein approach we employed. Lack of correlation between transcriptomic and proteomic data is now a well-recognized phenomenon [47] Additionally, the effects of acute (*in vitro*) vs. chronic (*in vivo*) PBDE exposures are not well understood. Moreover, considerably larger sample sizes are required to examine subtle effects in epidemiologic studies, due to substantial human variability that can diminish statistical power to detect a true association.

Our secondary analysis revealed reasonably consistent patterns of association between placental biomarkers and PBDE measurements in all three maternal-placental-fetal biological compartments, with stronger associations observed in combination with fetal liver PBDE levels. This may not be surprising, given the extreme interdependence of placental and fetal development during pregnancy, as well as the intricate coordination of hormones and molecular signaling pathways that drive biological changes and physiological adaptations between maternal, placental, and fetal compartments. Further efforts to identify possible mechanisms of placental PBDE toxicity relevant to fetal exposures are warranted.

Although we found no association between placental PBDE levels and the morphological endpoints we analyzed, our study is one of the first to characterize several important features of placental morphology during mid-gestation, a critical time of placentation about which current data is limited. Additionally, null associations are consistent with the fact that the types of changes we evaluated were indicative of severe placental disease and damage. Given that typical PBDE exposures during pregnancy are not consistently associated with overt pregnancy complications, it is likely that these (and other environmental chemicals) have more subtle effects that are difficult to discern. Identifying the most sensitive morphological endpoints during mid-gestation that are relevant for placenta-mediated diseases and incorporating additional molecular and clinical measures that have been shown to improve the diagnostic accuracy of complications like preeclampsia and fetal growth restriction (*i.e.*, placental growth factor, fms-like tyrosine kinase-1, and advanced ultrasound techniques) [13] would strengthen future research in this area.

In the time since we initiated this analysis, the application of new technologies for global profiling have emerged as a powerful way of answering important questions that are being raised about the effects of environmental chemical exposures on placental development. Many of these technologies could be applied to studies of similar design to ours in the future. For example, laser capture of specific trophoblast populations combined with global protein profiling by mass spectrometry could reveal interesting associations with environmental chemical exposures that are not biased toward molecules with well-studied roles in CTB differentiation and placental development. Also, discovering additional biomarkers of placental pathways (*e.g.*, oxidative stress, inflammation, angiogenesis, and/or hormone signaling) that are perturbed by PBDE exposures could yield valuable insights into how these chemicals impact pregnancy. Finally, given the explosive rate of placental development, it will be interesting to apply this approach across gestation to identify particularly important periods of vulnerability.

## 5. Conclusions

We found several molecular biomarkers that may be sensitive placental indicators of PBDE exposure. Our findings indicate that placental biomarkers of development and disease could be useful barometers of exposure to PBDEs, a paradigm that could be extended to other environmental chemicals and placental stage-specific antigens.

## Abbreviations

AV: Anchoring villi

BP: Basal plate

BMI: Body mass index

CDH5: Vascular endothelial-cadherin

CK: Cytokeratin

CTB: Cytotrophoblast

dAV: Distal anchoring villi

ECM: Extracellular matrix

eCTB: Endovascular CTB

EDC: Endocrine disrupting chemical

FV: Floating villi

H&E: Hematoxylin and Eosin

iCTB: Invasive/extravillous CTB

IF: Immunofluorescence

ITGA1: Integrin alpha-1

MDL: Method detection limit

MLE: Maximum likelihood estimation

MMP1: Metalloproteinase-1

MTBE: Methyl tert-butyl ether

pAV: Proximal anchoring villi

PBDE: Polybrominated diphenyl ethers

PFAS: Per- and polyfluorinated alkyl substances

SES: Socioeconomic status

STB: Syncytiotrophoblast

UCSF: University of California, San Francisco

US: United States

WBC: White blood cell

WOC: Women's Options Center

## **Declarations**

### **Ethics approval and consent to participate**

This study was approved by the University of California, San Francisco Institutional Review Board (UCSF IRB). Written and verbal consent were obtained from study participants prior to sample collection in accordance with the Declaration of Helsinki.

### **Consent for publication**

Not applicable.

### **Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

### **Competing interests**

The authors declare they have no actual or potential competing financial interests.

### **Funding**

This work was supported by the U.S. Environmental Protection Agency (No. RD-83543301) and the National Institute of Environmental Health Sciences (P01ES022841, R00ES023846), and the National Institute of Allergy and Infectious Diseases (K08AI141728 to SLG). These funding sources had no involvement in the conduct of the research or preparation of this article.

### **Authors' contributions**

JRV, JFR, SJF, and TJW designed and directed the project; YZ, JFR, KAP, EK, SB, and RA performed histological and molecular assessments of placental samples; JSP supervised and SCS and JF performed the chemical analysis of biological samples; JRV, SS, and JFR conducted the statistical analyses; JRV, JFR, SS, SLG, SJF, and TJW interpreted the experimental results; JRV and JFR constructed the figures; JRV, JFR, SJF, and TJW wrote the article. All authors read and approved the final manuscript.

### **Acknowledgements**

We thank all research participants and clinical staff at San Francisco General Hospital Women's Options Center (WOC) for assistance and support in this study. We specifically thank Erin DeMicco for study coordination and Cheryl Godwin de Medina for study recruitment and sample collection in the WOC.

## References

1. Leddy MA, Power ML, Schulkin J. The Impact of Maternal Obesity on Maternal and Fetal Health. *Rev Obstet Gynecol*. 2008;1:170–8.
2. ACOG. Committee opinion no. 575: Exposure to toxic environmental agents. American College of Obstetricians and Gynecologists (ACOG). *Obstet Gynecol*. 2013;122:931–4.
3. Ferguson KK, Chin HB. Environmental chemicals and preterm birth: Biological mechanisms and the state of the science. *Curr Epidemiol Rep*. 2017;4:56–71.
4. Varshavsky J. Heightened Susceptibility: A Review of How Pregnancy and Chemical Exposures Influence Maternal Health. *Reproductive Toxicology*. 2019;
5. Napso T, Yong HEJ, Lopez-Tello J, Sferruzzi-Perri AN. The Role of Placental Hormones in Mediating Maternal Adaptations to Support Pregnancy and Lactation. *Front Physiol* [Internet]. 2018 [cited 2018 Sep 5];9. Available from: <https://www.frontiersin.org/articles/10.3389/fphys.2018.01091/full>
6. Talbot L, Maclennan K. Physiology of pregnancy. *Anaesthesia & Intensive Care Medicine*. 2016;17:341–5.
7. Zhou Y, Fisher SJ, Janatpour M, Genbacev O, Dejana E, Wheelock M, et al. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? *J Clin Invest*. 1997;99:2139–51.
8. Fisher SJ. Why is placentation abnormal in preeclampsia? *Am J Obstet Gynecol*. 2015;213:S115–22.
9. Damsky CH, Librach C, Lim KH, Fitzgerald ML, McMaster MT, Janatpour M, et al. Integrin switching regulates normal trophoblast invasion. *Development*. 1994;120:3657–66.
10. Zhou Y, Damsky CH, Chiu K, Roberts JM, Fisher SJ. Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts. *J Clin Invest*. 1993;91:950–60.
11. Zhou Y, Damsky CH, Fisher SJ. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? *J Clin Invest*. 1997;99:2152–64.
12. Liu S, Diao L, Huang C, Li Y, Zeng Y, Kwak-Kim JYH. The role of decidual immune cells on human pregnancy. *Journal of Reproductive Immunology*. 2017;124:44–53.
13. Kingdom JC, Audette MC, Hobson SR, Windrim RC, Morgen E. A placenta clinic approach to the diagnosis and management of fetal growth restriction. *American Journal of Obstetrics and Gynecology*. 2018;218:S803–17.
14. Phuapittayalert L, Norkaew T, Supanpaiboon W, Chuenchoojit S, Hipkeao W, Swaddiwudhipong W, et al. Increasing of Syncytial Knot and Fibrinoid Deposit in High-Cd Accumulated Human Placentas. *Int J Morphol*. 2013;31:1210–5.

15. Poropat AE, Laidlaw MAS, Lanphear B, Ball A, Mielke HW. Blood lead and preeclampsia: A meta-analysis and review of implications. *Environ Res.* 2018;160:12–9.
16. Ilekis JV, Tsilou E, Fisher S, Abrahams VM, Soares MJ, Cross JC, et al. Placental origins of adverse pregnancy outcomes: potential molecular targets: an Executive Workshop Summary of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. *American Journal of Obstetrics and Gynecology.* 2016;215:S1–46.
17. ATSDR. Public Health Statement: Polybrominated Diphenyl Ethers (PBDEs) [Internet]. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry, Division of Toxicology and Human Health Sciences; 2017 Mar. Available from: <https://www.atsdr.cdc.gov/PHS/PHS.asp?id=1449&tid=183>
18. Leonetti C, Butt CM, Hoffman K, Miranda ML, Stapleton HM. Concentrations of polybrominated diphenyl ethers (PBDEs) and 2,4,6-tribromophenol in human placental tissues. *Environ Int.* 2016;88:23–9.
19. Zota AR, Mitro SD, Robinson JF, Hamilton EG, Park J-S, Parry E, et al. Polybrominated diphenyl ethers (PBDEs) and hydroxylated PBDE metabolites (OH-PBDEs) in maternal and fetal tissues, and associations with fetal cytochrome P450 gene expression. *Environ Int.* 2018;112:269–78.
20. Zhao X, Peng S, Xiang Y, Yang Y, Li J, Shan Z, et al. Correlation between Prenatal Exposure to Polybrominated Diphenyl Ethers (PBDEs) and Infant Birth Outcomes: A Meta-Analysis and an Experimental Study. *Int J Environ Res Public Health.* 2017;14.
21. Lam J, Lanphear BP, Bellinger D, Axelrad DA, McPartland J, Sutton P, et al. Developmental PBDE Exposure and IQ/ADHD in Childhood: A Systematic Review and Meta-analysis. *Environ Health Perspect* [Internet]. 2017 [cited 2019 Mar 21];125. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783655/>
22. Zota AR, Rudel RA, Morello-Frosch RA, Brody JG. Elevated house dust and serum concentrations of PBDEs in California: unintended consequences of furniture flammability standards? *Environ Sci Technol.* 2008;42:8158–64.
23. Yu L, Han Z, Liu C. A review on the effects of PBDEs on thyroid and reproduction systems in fish. *Gen Comp Endocrinol.* 2015;219:64–73.
24. Park H-R, Loch-Caruso R. Protective effect of ( $\pm$ ) $\alpha$ -tocopherol on brominated diphenyl ether-47-stimulated prostaglandin pathways in human extravillous trophoblasts in vitro. *Toxicol In Vitro.* 2015;29:1309–18.
25. Park H-R, Kamau PW, Korte C, Loch-Caruso R. Tetrabromobisphenol A Activates Inflammatory Pathways in Human First Trimester Extravillous Trophoblasts in vitro. *Reprod Toxicol.* 2014;50:154–62.
26. Park H-R, Loch-Caruso R. Protective Effect of Nuclear Factor E2-Related Factor 2 on Inflammatory Cytokine Response to Brominated Diphenyl Ether-47 in the HTR-8/SVneo Human First Trimester Extravillous Trophoblast Cell Line. *Toxicol Appl Pharmacol.* 2014;281:67–77.

27. Peltier MR, Klimova NG, Arita Y, Gurzenda EM, Murthy A, Chawala K, et al. Polybrominated diphenyl ethers enhance the production of proinflammatory cytokines by the placenta. *Placenta*. 2012;33:745–9.
28. Arita Y, Yeh C, Thoma T, Getahun D, Menon R, Peltier MR. Effect of polybrominated diphenyl ether congeners on placental cytokine production. *J Reprod Immunol*. 2018;125:72–9.
29. Leonetti CP, Butt CM, Stapleton HM. Disruption of thyroid hormone sulfotransferase activity by brominated flame retardant chemicals in the human choriocarcinoma placenta cell line, BeWo. *Chemosphere*. 2018;197:81–8.
30. Zhu Y, Tan YQ, Leung LK. Exposure to 2,2',4,4'-tetrabromodiphenyl ether at late gestation modulates placental signaling molecules in the mouse model. *Chemosphere*. 2017;181:289–95.
31. Zhu Y, Tan YQ, Wang CC, Leung LK. The flame retardant 2,2',4,4'-Tetrabromodiphenyl ether enhances the expression of corticotropin-releasing hormone in the placental cell model JEG-3. *Chemosphere*. 2017;174:499–505.
32. Damsky CH, Fitzgerald ML, Fisher SJ. Distribution patterns of extracellular matrix components and adhesion receptors are intricately modulated during first trimester cytotrophoblast differentiation along the invasive pathway, in vivo. *J Clin Invest*. 1992;89:210–22.
33. Morello-Frosch R, Cushing LJ, Jesdale BM, Schwartz JM, Guo W, Guo T, et al. Environmental Chemicals in an Urban Population of Pregnant Women and Their Newborns from San Francisco. *Environ Sci Technol*. 2016;50:12464–72.
34. Whitehead TP, Smith SC, Park J-S, Petreas MX, Rappaport SM, Metayer C. Concentrations of persistent organic pollutants in California women's serum and residential dust. *Environ Res*. 2015;136:57–66.
35. Phillips DL, Smith AB, Burse VW, Steele GK, Needham LL, Hannon WH. Half-Life of Polychlorinated Biphenyls in Occupationally Exposed Workers. *Archives of Environmental Health: An International Journal*. 1989;44:351–4.
36. Vettraino IM, Roby J, Tolley T, Parks WC. Collagenase-I, stromelysin-I, and matrilysin are expressed within the placenta during multiple stages of human pregnancy. *Placenta*. 1996;17:557–63.
37. Schisterman EF, Whitcomb BW, Buck Louis GM, Louis TA. Lipid Adjustment in the Analysis of Environmental Contaminants and Human Health Risks. *Environ Health Perspect*. 2005;113:853–7.
38. O'Brien KM, Upson K, Cook NR, Weinberg CR. Environmental Chemicals in Urine and Blood: Improving Methods for Creatinine and Lipid Adjustment. *Environmental Health Perspectives*. 2016;124:220–7.
39. Helsel DR. *Nondetects and Data Analysis: Statistics for Environmental Data*. Hoboken, New Jersey: John Wiley & Sons Ltd; 2005.
40. R Core Team. *R: A language and environment for statistical computing*. [Internet]. Vienna, Austria.; 2018. Available from: <https://www.R-project.org/>.
41. Lopaka Lee. *NADA: Nondetects and Data Analysis for Environmental Data*. [Internet]. 2017. Available from: <https://CRAN.R-project.org/package=NADA>

42. Akritas, M.G., , S. A. Murphy, and M. P. LaValley. The Theil-Sen Estimator With Doubly Censored Data and Applications to Astronomy. *Journ Amer Statistical Assoc.* 1995;90.
43. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. 1995;57:289–300.
44. Zhu J-Y, Pang Z-J, Yu Y. Regulation of Trophoblast Invasion: The Role of Matrix Metalloproteinases. *Rev Obstet Gynecol.* 2012;5:e137–43.
45. Lan X, Fu L-J, Zhang J, Liu X-Q, Zhang H-J, Zhang X, et al. Bisphenol A exposure promotes HTR-8/SVneo cell migration and impairs mouse placentation involving upregulation of integrin- $\beta$ 1 and MMP-9 and stimulation of MAPK and PI3K signaling pathways. *Oncotarget.* 2017;8:51507–21.
46. Robinson JF, Kapidzic M, Hamilton EG, Chen H, Puckett KW, Zhou Y, et al. Genomic Profiling of BDE-47 Effects on Human Placental Cytotrophoblasts. *Toxicol Sci.* 2019;167:211–26.
47. Haider S, Pal R. Integrated Analysis of Transcriptomic and Proteomic Data. *Curr Genomics.* 2013;14:91–110.
48. Maltepe E, Fisher SJ. Placenta: The Forgotten Organ. *Annual Review of Cell and Developmental Biology.* 2015;31:523–52.

## Tables

## Figures

**TABLE 1.** Population characteristics and placental PBDE levels during mid-gestation at the Women's Options Center (WOC) in Northern California, 2014-16 (n=135)

Population Characteristic	n (%)	Wet-weight BDE-47		Lipid-adjusted BDE-47		Wet-weight $\Sigma$ PBDE4		Lipid-adjusted $\Sigma$ PBDE4	
		GM (95% CI)	p-Value <sup>a</sup>	GM (95% CI)	p-Value <sup>a</sup>	GM (95% CI)	p-Value <sup>a</sup>	GM (95% CI)	p-Value <sup>a</sup>
<b>Maternal Age</b>									
< 20 yrs	19 (14)	0.10 (0.08, 0.14)	0.910	11.1 (8.4, 14.6)	0.945	0.20 (0.16, 0.26)	0.922	21.6 (16.9, 27.5)	0.893
20-24 yrs	58 (43)	0.10 (0.08, 0.14)		10.8 (7.8, 14.9)		0.20 (0.15, 0.27)		20.9 (15.7, 27.8)	
25-29 yrs	30 (22)	0.10 (0.07, 0.14)		11.1 (7.7, 15.8)		0.20 (0.14, 0.27)		22.1 (16.1, 30.4)	
$\geq$ 30 yrs	29 (21)	0.10 (0.07, 0.15)		11.3 (7.8, 16.2)		0.19 (0.14, 0.26)		21.0 (15.3, 29.0)	
<b>Gestational Age</b>									
< 19 wks	37 (27)	0.11 (0.09, 0.13)	0.255	11.6 (9.5, 14.1)	0.601	0.21 (0.18, 0.25)	0.440	22.4 (18.8, 26.8)	0.756
19-21 wks	51 (38)	0.11 (0.09, 0.14)		11.3 (8.7, 14.8)		0.21 (0.16, 0.26)		21.3 (16.8, 26.9)	
$\geq$ 21 wks	48 (35)	0.09 (0.07, 0.12)		10.2 (7.8, 13.4)		0.18 (0.15, 0.23)		20.5 (16.2, 26.0)	
<b>Body Mass Index (BMI)</b>									
Normal/Under (< 25 kg/m <sup>2</sup> )	59 (43)	0.10 (0.08, 0.11)	0.602	10.8 (9.2, 12.7)	0.795	0.19 (0.16, 0.22)	0.594	21.1 (18.3, 24.3)	0.652
Overweight (25-30 kg/m <sup>2</sup> )	38 (28)	0.11 (0.09, 0.14)		10.6 (8.1, 13.7)		0.21 (0.17, 0.26)		20.2 (16.1, 25.5)	
Obese ( $\geq$ 30 kg/m <sup>2</sup> )	39 (29)	0.10 (0.08, 0.13)		11.6 (9.0, 15.0)		0.20 (0.16, 0.25)		22.7 (18.2, 28.4)	
<b>Parity</b>									
0 births	55 (40)	0.09 (0.08, 0.11)	0.309	9.9 (8.4, 11.6)	0.240	0.19 (0.16, 0.21)	0.443	19.6 (16.9, 22.6)	0.325
$\geq$ 1 birth	81 (60)	0.11 (0.09, 0.13)		11.9 (9.6, 14.7)		0.21 (0.17, 0.25)		22.6 (18.7, 27.4)	
<b>Fetal Sex</b>									
Male	73 (54)	0.10 (0.09, 0.12)	0.955	10.2 (8.8, 11.8)	0.379	0.20 (0.18, 0.23)	0.942	20.4 (18.0, 23.3)	0.659
Female	63 (46)	0.10 (0.09, 0.13)		11.9 (9.6, 14.7)		0.20 (0.16, 0.23)		22.3 (18.5, 26.9)	
<b>Education</b>									
$\leq$ High School	67 (49)	0.11 (0.10, 0.13)	0.260	11.9 (10.2, 13.8)	0.415	0.22 (0.19, 0.25)	0.177	23.1 (20.2, 26.3)	0.308

≥ Some college	68 (50)	0.09 (0.08, 0.12)		10.3 (8.3, 12.7)		0.18 (0.15, 0.22)		19.9 (16.5, 24.0)	
<b>Insurance</b>									
Public	98 (72)	0.11 (0.10, 0.12)	0.364	11.7 (10.3, 13.3)	0.159	0.21 (0.19, 0.23)	0.222	22.7 (20.4, 25.3)	<b>0.066</b>
Private/Self-pay	37 (27)	0.09 (0.07, 0.11)		9.3 (7.3, 11.7)		0.17 (0.14, 0.21)		17.7 (14.4, 21.8)	
<b>Race/ethnicity</b>									
Latina/Hispanic	45 (33)	0.10 (0.09, 0.12)	0.102	10.2 (8.6, 12.1)	<b>0.038</b>	0.19 (0.16, 0.22)	<b>0.011</b>	18.8 (16.2, 21.8)	<b>0.001</b>
Non-Hispanic Black	31 (23)	0.12 (0.09, 0.16)		13.7 (10.4, 17.9)		0.24 (0.19, 0.31)		27.6 (21.9, 34.8)	
Non-Hispanic White	20 (15)	0.09 (0.07, 0.13)		10.6 (7.8, 14.4)		0.18 (0.14, 0.23)		20.2 (15.4, 26.3)	
Asian/Pacific Islander	17 (12)	0.09 (0.06, 0.12)		9.2 (6.6, 12.7)		0.16 (0.12, 0.21)		17.0 (12.8, 22.6)	
<b>Birth Country</b>									
U.S. born	71 (52)	0.11 (0.10, 0.13)	0.114	11.8 (10.3, 13.6)	0.222	0.21 (0.19, 0.23)	<b>0.009</b>	22.4 (19.9, 25.3)	<b>0.025</b>
Foreign born	9 (7)	0.07 (0.05, 0.11)		8.3 (5.5, 12.4)		0.12 (0.08, 0.17)		13.5 (9.4, 19.3)	
<b>Collection Year</b>									
2014	33 (24)	0.11 (0.09, 0.13)	<b>0.032</b>	13.8 (11.3, 16.9)	<b>0.004</b>	0.20 (0.17, 0.24)	0.125	24.8 (20.7, 29.7)	<b>0.037</b>
2015	93 (68)	0.10 (0.08, 0.12)		9.8 (7.7, 12.3)		0.19 (0.16, 0.24)		19.6 (15.9, 24.3)	
2016	10 (7)	0.16 (0.10, 0.26)		15.9 (10.0, 25.3)		0.29 (0.19, 0.43)		28.0 (18.4, 42.5)	
<i>Total (pooled)<sup>b</sup></i>	<i>135 (100)</i>	<i>0.10 (0.09; 0.03- 0.92)</i>		<i>11.0 (9.7; 3.1- 107)</i>		<i>0.20 (0.15; 0.07-1.3)</i>		<i>21.3 (16.4; 5.8- 152)</i>	

GM = Geometric mean; IQR = Interquartile range (25<sup>th</sup>-75<sup>th</sup> percentile).

† Number (%) missing = 56 (41), 1 (0.7), 1 (0.7), and 23 (17) for birth country, education, insurance, and race/ethnicity, respectively.

<sup>a</sup> P-values from ANOVA test of mean difference in Ln BDE levels between population characteristic subgroups. P < 0.10 bolded.


<sup>b</sup> Summary statistics of placental PBDE levels in total (pooled) study population, including: GM (IQR; Min-Max).

**TABLE 2.** Descriptive statistics of morphological placental biomarkers and correlation<sup>a</sup> with gestational age during mid-gestation (n=61)

<i>Morphological Biomarker</i>	<i>n</i>	<i>Mean</i>	<i>Median</i>	<i>SD</i>	<i>Min</i>	<i>Max</i>	<i>Gestational Age (Weeks)</i>	
							<i>Tau</i>	<i>p-Value</i>
Average White Blood Cell / image	61	212	157	174	0.00	950	-0.12	0.179
% Floating Villi with Fibrinoid Deposition (binary)	61	13.4	11.8	10.4	0.10	47.1	-0.28	0.001
% Fibrinoid Deposition in Basal Plate (area)	61	22.6	20.0	19.6	0.00	78.0	0.02	0.866
% CTB-modulated Uterine Spiral Arteries	38	71.7	80.6	30.4	0.00	100	-0.14	0.240

CTB = Cytotrophoblast; SD = Standard deviation.

<sup>a</sup> Non-parametric rank order correlation assessed using Kendall's Tau Correlation Coefficient.



**Figure 1**

Human placental villous cytotrophoblast (CTB) differentiation at the maternal-fetal interface. (A) Anatomy of the human placenta. Chorionic villi are the functional units. The histology of the boxed area is shown in the panel to the right. (B) Depiction of the maternal-fetal interface at the cellular level. The mononuclear cytotrophoblasts (CTB) of the (early gestation) chorionic villi fuse to become multinuclear syncytiotrophoblasts (STBs), which form the surface of the placenta. Floating villi are perfused by maternal blood. Anchoring villi give rise to invasive interstitial CTBs (CTBi) that emigrate from the chorionic villi via cell columns that attach the placenta to the maternal unit and infiltrate the uterine wall. Maternal cells in this region include the decidua, remodeled uterine blood vessels, which are lined by cytotrophoblasts (CTBe), and immune cells. During vascular invasion, the cells breach both veins and arteries, but they have more extensive interactions with the arterial portion of the uterine vasculature. Here, they replace the endothelial lining and intercalate within the smooth muscle walls of the spiral arteries, producing hybrid vessels that are composed of both embryonic/fetal and maternal cells. Vascular invasion connects the uterine circulation to the intervillous space where maternal blood perfuses the chorionic villi. Immunoreactivity of molecular biomarkers was evaluated in five zones (I-V)

**TABLE 3.** Percent (%) difference in placental PBDE levels between molecular immunoreactivity groups for each biomarker within each placental region/cell type during mid-gestation (n=62)

<i>Immunoreactivity</i>	<i>n</i>	Wet-weight BDE-47 (ng/g)		Wet-weight $\Sigma$ PBDE4 (ng/g)		Lipid-adjusted BDE-47 (ng/g lipid)		Lipid-adjusted $\Sigma$ PBDE4 (ng/g lipid)		
		% diff (95% CI) <sup>a</sup>	<i>p</i> -value <sup>b</sup>	% diff (95% CI) <sup>a</sup>	<i>p</i> -value <sup>b</sup>	% diff (95% CI) <sup>a</sup>	<i>p</i> -value <sup>b</sup>	% diff (95% CI) <sup>a</sup>	<i>p</i> -value <sup>b</sup>	
<b>Anchoring Villi (proximal)</b>										
<i>ITGA1</i>	<25% (-)	48	Referent	0.616	Referent	0.433	Referent	0.813	Referent	0.724
	25-75% (-/+)	2	68 (-44, 403)		82 (-32, 385)		38 (-56, 331)		49 (-46, 316)	
	>75% (+)	2	-16.(-72, 151)		-21 (-70, 110)		23 (-61, 283)		15 (-59, 221)	
<i>CHD5</i>	<25% (-)	11	Referent	0.502	Referent	0.404	Referent	0.441	Referent	0.357
	25-75% (-/+)	21	35 (-20, 130)		39 (-14, 125)		39 (-20, 142)		43 (-13, 136)	
	>75% (+)	21	13 (-34, 91)		21 (-25, 94.8)		11 (-36, 93)		19 (-28, 96)	
<i>MMP1</i>	<25% (-)	1	Referent	0.395	Referent	0.472	Referent	0.741	Referent	0.862
	25-75% (-/+)	30	109 (-51, 797)		56 (-58, 481)		69 (-64, 700)		26 (-69, 413)	
	>75% (+)	20	67 (-61, 626)		2 (-6, 375)		51 (-69, 627)		14 (-72, 371)	
<b>Anchoring Villi (distal)</b>										
<i>ITGA1</i>	<25% (-)	38	Referent	0.759	Referent	0.837	Referent	0.599	Referent	0.739
	25-75% (-/+)	3	-19 (-68, 102)		4.1 (-54, 138)		-28 (-72, 83)		-7.8 (-61, 116)	
	>75% (+)	11	15 (-32, 94)		15 (-28, 85)		19 (-30, 104)		20 (-26, 95)	
<i>CHD5</i>	<25% (-)	9	Referent	0.670	Referent	0.550	Referent	0.662	Referent	0.542
	25-75% (-/+)	24	29 (-26, 125)		32 (-20, 120)		31 (-27, 135)		35 (-21, 128)	
	>75% (+)	20	17 (-34, 108)		19 (-29, 100)		19 (-35, 117)		21 (-30, 108)	
<i>MMP1</i>	<25% (-)	0	Referent	0.901	Referent	0.944	Referent	0.661	Referent	0.697
	25-75% (-/+)	25	-9.1 (-40, 37)		-6.2 (-35, 36)		-18 (-47, 26)		-15 (-43, 24)	
	>75% (+)	26	--		--		0.0 (0.0, 0.0)		0.0 (0.0, 0.0)	
<b>Interstitial CTB</b>										
<i>ITGA1</i>	<25% (-)	6	Referent	0.622	Referent	0.556	Referent	0.881	Referent	0.863
	25-75% (-/+)	24	-16 (-58, 66)		-17.1 (-55, 53)		-3.5 (-53, 98)		-4.4 (-49, 81)	
	>75% (+)	30	2.3 (-48, 101)		1.07 (-45, 85)		7.6 (-47, 117)		6.3 (-43, 99)	
<i>CHD5</i>	<25% (-)	8	Referent	<b>0.032**</b>	Referent	<b>0.028**</b>	Referent	<b>0.018**</b>	Referent	<b>0.019**</b>
	25-75% (-/+)	14	<b>138 (26, 350)***</b>		<b>115 (22, 279)***</b>		<b>163 (37, 405)***</b>		<b>137 (33, 325)***</b>	
	>75% (+)	38	<b>63 (-6.6, 185)*</b>		42 (-14, 133)		<b>102 (14, 257)**</b>		<b>75 (5.3, 192)**</b>	
<i>MMP1</i>	<25% (-)	2	Referent	0.372	Referent	0.350	Referent	0.693	Referent	0.727
	25-75% (-/+)	23	41 (-53, 324)		-0.38 (-63, 167)		36 (-57, 330)		-4.1 (-66, 168)	


	>75% (+)	35	77 (-40, 425)		29 (-51, 242)		53 (-51, 376)		12 (-59, 208)	
<b>Endovascular CTB</b>										
<i>ITGA1</i>	<25% (-)	6	Referent	0.303	Referent	0.211	Referent	0.518	Referent	0.386
	25-75% (-/+)	5	-30 (-73, 80)		-22 (-65, 73)		-9.3 (-66, 145)		1.0 (-57, 135)	
	>75% (+)	18	-44 (-73, 16)		<b>-42 (-69, 7.2)*</b>		-34 (-69, 44)		-31 (-64, 32)	
<i>CHD5</i>	<25% (-)	8	Referent	0.256	Referent	0.175	Referent	0.145	Referent	0.151
	25-75% (-/+)	3	140 (-16, 590)		<b>146 (-2.8, 521)*</b>		134 (-21, 588)		<b>139 (-8.3, 522)*</b>	
	>75% (+)	31	42 (-24, 162)		23 (-29, 112)		82.4 (-3.2, 243)		59 (-9.5, 178)	
<i>MMP1</i>	<25% (-)	11	Referent	0.883	Referent	0.846	Referent	0.847	Referent	0.736
	25-75% (-/+)	20	12 (-40, 110)		1.1 (-42, 77)		8.0 (-43, 106)		-2.8 (-45, 73)	
	>75% (+)	5	-6.6 (-6, 130)		-19 (-64, 83)		-16 (-67, 113)		-27 (-68, 67)	

\*p < 0.10. \*\* p < 0.05. \*\*\* p < 0.01. Significant and marginally significant results bolded.

<sup>a</sup> Calculated from bivariate censored regression models, where referent group included placental samples with trophoblast cells (identified as cytokeratin+ cells) that did not stain (-) or stained only minimally (0-25%) for antigen specific antibodies corresponding to each molecular biomarker.


<sup>b</sup> P-value from ANOVA test of mean difference in Ln PBDE level across three immunoreactivity groups.

corresponding to different stages of CTB differentiation: I) CTB progenitors in floating villi (FV); II) CTBs of the proximal (AVp) and III) distal (AVd) anchoring villi; IV) invading interstitial CTBs (CTBi); and V) endovascular CTBs (CTBe) that remodel the uterine vasculature. Image modified from Maltepe and Fisher, 2015; Damsky et al., 1992 (Damsky et al., 1992; Maltepe and Fisher, 2015).




**Figure 2**

Participant recruitment and biological samples collected at the Women's Options Center (WOC) in Northern California from 2014–16. We obtained tissue samples and questionnaire data from 138 pregnant women undergoing elective terminations during mid-gestation. Polybrominated diphenyl ether (PBDE) levels were measured in 135 placental samples. After excluding twins, PBDE measurements were obtained for 130 matched samples of maternal serum, fetal liver, and the placenta. Then we evaluated a subset of placental samples for molecular (n = 62) and morphological (n = 61) biomarkers of placental development and disease.



**Figure 3**

Immunoreactivity of ITGA1, CDH5, and MMP1 as a function of cytotrophoblast (CTB) differentiation/invasion during mid-gestation (n=62). The following cell types were scored: 1) CTBs in floating villi (FV); anchoring villi CTBs in the 2) proximal (pAV) and 3) distal (dAV) regions of cell columns; 4) invasive interstitial CTBs (iCTB); and 5) endovascular CTBs (eCTB). CTB immunoreactivity in each region was scored based on the percent of cells that stained for each biomarker in that region: 1) < 25% (-), 2) 25–75% (-/+), or 3) > 75% (+). Staining patterns varied by antigen and CTB subtype (p< 0.001; Fisher’s exact test).



**Figure 4**

Wet-weight placental (A) BDE-47 and (B)  $\sum$ PBDE4 molecular immunoreactivity by placental region/cell type during mid-gestation (n=62).  $\sum$ PBDE4 = BDE-47 + -99 + -100 + -153. Red asterisks denote significance or marginal significance (where: \*p < 0.10; \*\*p < 0.05; and \*\*\*p < 0.01) from bivariate censored MLE regression models evaluating the percent (%) difference in placental PBDE levels between moderate or high immunoreactivity compared to low immunoreactivity/referent group: 25–75% (-/+ or > 75% (+) compared to < 25% (-).

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementalTablesPlacentalBiomarkersSUBMITTED.docx](#)
- [SupplementalFiguresPlacentalBiomarkersSUBMITTED.pdf](#)